- Home
- CEPF vs ZVRA Comparison
CEPF vs ZVRA Comparison
Compare CEPF & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$9.41
Company Overview
Basic Information| Metric | CEPF | ZVRA |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.6M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CEPF | ZVRA |
|---|---|---|
| Price | $10.26 | $9.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 42.6K | ★ 1.0M |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $38.67 |
| Revenue Next Year | N/A | $53.63 |
| P/E Ratio | $96.45 | ★ $6.82 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $10.09 | $6.19 |
| 52 Week High | $10.67 | $13.16 |
Technical Indicators
Market Signals| Indicator | CEPF | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 51.05 |
| Support Level | $10.18 | $8.33 |
| Resistance Level | $10.65 | $9.44 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 23.68 | 35.38 |
Price Performance
Historical Comparison CEPF
ZVRA
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.